在不确定性中寻找确定性 华商基金实力派胡中原“固收+”新品正在发售

Core Viewpoint - The "Fixed Income +" product, leveraging a bond foundation with equity enhancements, is positioned as an optimal choice for investors seeking to balance risk and return in a low-interest-rate environment with structural opportunities in the equity market [1][9]. Fund Overview - The Huashang Anyuan Bond Fund (Class A: 026045, Class C: 026046) is launched by Huashang Fund, aiming to provide a high-quality investment experience characterized by "steady progress" in a complex market [1][9]. - The fund plans to allocate no less than 80% of its assets to bond investments, establishing a base yield and safety net, while flexibly investing 5%-20% in equities, convertible bonds, and exchangeable bonds to enhance return elasticity [1][15]. Fund Management - The fund will be managed by Hu Zhongyuan, Deputy General Manager of the Multi-Asset Investment Department at Huashang Fund, who possesses a comprehensive background in both equity and bond investments, providing a natural advantage in managing "Fixed Income +" products [3][17]. - Hu Zhongyuan has over 11 years of experience in the securities industry, with 6.5 years specifically in securities investment, emphasizing a risk-return priority in his investment philosophy [4][18]. Investment Strategy - Hu Zhongyuan's investment approach includes cautious credit quality management in bond investments and a focus on industry comparisons for equity selection, maintaining a dual diversification principle in portfolio management [5][18]. - The fund aims to capitalize on investment opportunities in both bond and equity markets while controlling volatility, seeking long-term stable asset appreciation [1][15]. Market Context - The current market conditions suggest that the return elasticity of "Fixed Income +" products is increasingly derived from equity assets, aligning with Hu Zhongyuan's perspective that the equity market can be positively influenced by policy support and liquidity easing [8][21]. - Hu Zhongyuan will focus on opportunities arising from artificial intelligence, demographic changes, and advancements in China's pharmaceutical innovation, particularly in the consumer and pharmaceutical sectors [21]. Research and Support - Huashang Fund has established a robust research and investment platform, recognized for its comprehensive capabilities in active management, receiving multiple 5A ratings in various categories from Tianxiang Investment Consulting [21][24]. - As of September 30, 2025, Huashang Fund's active fixed income funds ranked first in absolute returns over the past seven years, while its active equity funds ranked second, showcasing its strong capabilities in integrated asset management [21][26].